Skip to content

Public FDA record

Z-1905-2021: Access SARS CoV-2 lgG II Reagent, REF: C69057, IVD CE UDI: (01)15099590742744

Recall record Z-1905-2021 for Beckman Coulter Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1905-2021
Company in FDA record
Beckman Coulter Inc.
FDA record creation date
Jun 21, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

SARS-CoV-2 lgG II numerical results may potentially be multiplied by a factor of 1000 on systems running with assay protocol file (APF) and access assay file (AAF) versions resulting in falsely elevated numerical values.

Source facts

Action
On May 7, 2021, Beckman Coulter issued an "URGENT MEDICAL DEVICE RECALL" to affected consignees. The notification was emailed and sent via First Class Mail. In addition to informing consignees about the recall, the firm ask consignees to take the following actions: 1. Do not install any of the APF/AAF versions listed in the table. 2. Determine your current APF/AAF version. " From the Main Menu: select Configure F8 System Setup F1 System Revisions F1. " Verify the APF/AAF version displayed on the screen. 3 If the APF/AAF version is listed in the table: " Stop using the Access SARS-CoV-2 IgG II assay. Contact the Beckman Coulter Customer Technical Support Center at 1-800-854-3633 for further instruction. " Review all Access SARS-CoV-2 IgG II patient test results from April 13, 2021 onward. " Do not install any additional APF/AAF versions prior to contacting Beckman Coulter. 4. If the APF/AAF version is lower than those listed in the table, you are not impacted. Continue operating your system under existing instructions. 5. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them a copy of this letter. 6. So that we are assured you have received this important communication, please respond within 10 days in one of the following ways: " Electronically, if you received this communication via email. " Manually, complete and return the enclosed Response Form. 7. If you have any questions regarding this notice, please contact our Customer Support Center: " From our website: http://www.beckmancoulter.com " By phone: call 1-800-854-3633 in the United States.
Initiated
2021-05-07
Root cause
Software Design Change
Terminated
2023-03-27
Distribution
US: Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, New Jersey, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Puerto Rico, Tennessee, Texas, Virginia, West Virginia, Wisconsin, Wyoming, OUS: Andorra, Austria, Croatia, Czech Republic, France, Germany, Gibraltar, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Jordan, Poland, Portugal, San Marino, Slovakia, Slovenia, Spain, United Arab Emirates
Recall number
Z-1905-2021
Recall status
Terminated
CDRH record ID
187543
FDA record created
2021-06-21
Recall event number
87960

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗